[Skip to Navigation]
Invited Commentary
Feb 11, 2013

Generic Pills From the Patient Perspective: Comment on “Variations in Pill Appearance of Antiepileptic Drugs and the Risk of Nonadherence”

Author Affiliations

Author Affiliations: Office of Generic Drugs, US Food and Drug Administration, Rockville, Maryland.

JAMA Intern Med. 2013;173(3):208-209. doi:10.1001/jamainternmed.2013.2283

Generic drug products are becoming increasingly important to health care. Nearly 80% of prescriptions filled in the United States are for generic drugs. At the US Food and Drug Administration (FDA), the Office of Generic Drugs (OGD) is responsible for the approval of generic drug products. The OGD assesses the safety, efficacy, and quality of generic drug products by making a finding of pharmaceutical equivalence and “bioequivalence.” A key principle is that generic drug products that reach health care providers and patients must be scientifically verified as appropriately substitutable for the brand-name products that are listed by the FDA as reference products.

Add or change institution